Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inhaler Manufacturer Board Approves Takeover By Tobacco Company

Executive Summary

The board members of Vectura, a manufacturer of inhalers and inhaled drugs, have approved a $1.4bn takeover bid by Philip Morris International, the manufacturer of Marlboro cigarettes.

You may also be interested in...



Carlyle Cancels Vectura Auction At Eleventh Hour As Bid Declared Final

Private equity group Carlyle has pulled the plug on a potential auction to take control of the UK-based Vectura group by declaring final its revised bid for the respiratory specialist. Tobacco giant Philip Morris had offered a 10% premium to Carlyle’s bid.

Point Of Care Diagnostics Market Projected To Continue Rapid Growth

A new report from Informa's Meddevicetracker highlights strong projected growth in the market, explaining the underlying reasons why.

Pear Therapeutics Obtains First Medicaid Coverage For PDTs

Massachusetts’ Medicaid program will cover reSET and reSET-O prescription digital therapeutics for the treatment of substance abuse disorder and opioid use disorder.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144340

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel